Evidence map›Paper›PMID 33063942›Full record

ArticlePediatric blood & cancer2021

Low-grade glioma: A rare second tumor in retinoblastoma survivors.

Nagma Dalvi, Ruth A Kleinerman, Sidnei Epelman, David H Abramson, Ira J Dunkel

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric blood & cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Nagma DalviDepartments of Pediatrics and Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Ruth A KleinermanDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland.
Sidnei EpelmanSanta Marcelina Hospital, Sao Paulo, Brazil.
David H AbramsonDepartments of Ophthalmology and Pediatrics, Weill Cornell Medical College, New York, New York.
Ira J DunkelDepartments of Pediatrics and Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-8091-6067
Memorial Sloan Kettering Cancer Center · USCornell University · USHospital Santa Marcelina · BRNational Cancer Institute · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Intramural NIH HHSNCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Retinoblastoma survivors with a germline RB1 mutation are at elevated risk for secondary (nonocular) malignancy, but their risk for low-grade glioma (LGG) is unknown. We performed a retrospective review of the Memorial Sloan Kettering Cancer Center and the NCI databases that revealed that three of the 837 5-year survivors of hereditary retinoblastoma were diagnosed with an LGG and a fourth patient (but unilateral and without a germline mutation) was identified at another center. Retinoblastoma survivors may be at increased risk for LGG.

Indexed as

AdolescentCerebellumFemaleGenetic Predisposition to DiseaseGliomaHumansMaleNeoplasms, Second PrimaryRetinal NeoplasmsRetinoblastomaRetinoblastoma Binding ProteinsTemporal LobeUbiquitin-Protein LigasesYoung AdultRB1 protein, humanRetinoblastoma Binding ProteinsUbiquitin-Protein Ligaseslow-grade gliomaretinoblastomasecond cancerssurvivorship

Identifiers

PMID33063942
PMCPMC8376183
OpenAlexW3092913148

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.